[Combined gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer].
OBJECTIVE
To investigate the clinical efficacy and side effects of advanced non-small cell lung cancer (NSCLC) treated by combined gemcitabine and cisplatin.


METHODS
Forty-six patients with locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC were alloted to the study. The patients received gemcitabine 1 000 mg/m(2) on D 1, 8, and cisplatin 80 mg on D 1 approximately 3 in the 21-day cycle.


RESULTS
An objective response was obtained in 46% (21/46) of patients (1 CR and 21 PR), whereas 19 patients had stable disease and 6 patients showed progressive disease. The response rate was 58.3% in untreated patients and 31.8% was obtained in treated ones. Significant difference was observed between the two groups (P < 0.05). The main toxicities were leukopenia and thrombocytopenia.


CONCLUSIONS
The combination of gemcitabine and cisplatin, being feasible and well-tolerated, should be taken as an energetic scheme in the treatment of advanced NSCLC.
Wang
Li-ping
LP
Department of Oncology, First Hospital, Zhengzhou University, Zhengzhou 450052, China.
Mei
Qi-da
QD
Gao
Guo-qian
GQ
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000093542:Gemcitabine
D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine